Summary
Clinical and experimental observations have confirmed that an episodic increase in the vasomotor tone of a major coronary artery may play a pathogenetic role not only in “variant angina” but also in other, more common anginal syndromes. In chronic stable angina, dynamic changes of vascular smooth muscle tone at the site of eccentric atheromatous plaques are responsible for “mixed angina.” Abnormal coronary vasomotion contributes to myocardial ischemia in acute coronary syndromes as well. Studies have shown that a “primary” reduction of coronary blood flow, usually associated with plaque fissuring and thrombus formation, causes infarction and unstable angina. Abnormal vasoconstriction associated with the release of vasoactive substances by platelets and other constituents of the thrombus can contribute to coronary flow reduction in patients with unstable angina and myocardial infarction. Better understanding of the complex interactions among atherosclerotic coronary obstructions, the vascular smooth muscle, and the vascular endothelium has resulted in novel therapeutic approaches and has stimulated the search for more efficacious and safer coronary vasodilators. Recently interest has focused on vasodilator agents such as nicorandil that influence coronary arterial tone by acting through potassium channel activation. Nicorandil appears to be effective for treatment of vasospastic angina, as suggested by studies in Japan and Europe. In addition to its “antivasospastic” properties, nicorandil dilates coronary artery stenoses in patients with stable angina pectoris. It also improves myocardial ischemia in patients with mixed angina. Thus nicorandil may be useful for treatment of patients with “variable threshold angina” in whom myocardial ischemia results from the combined effects of obstructive coronary plaques and changes of coronary vasomotor tone.
Similar content being viewed by others
References
Kaski J, Maseri A. Clinical significance of coronary vasomotor tone in myocardial ischaemia. In: Heusch G, ed.Pathophysiology and Rational Pharmacotherapy of Myocardial Ischaemia. New York: Springer-Verlag, 1990;1990:217–229.
Maseri A, Davies G, Hackett D, Kaski J. Coronary artery spasm and vasoconstriction: The case for a distinction.Circulation 1990;81:1983–1991.
Pickering GW. Vascular spasm.Lancet 1951;2:845–850.
Maseri A, Chierchia S. Coronary artery spasm: Demonstration, definition, diagnosis and consequences.Prog Cardiovasc Dis 1982;25:169–192.
Antman E, Muller J, Golderberg S, et al. Nifedipine therapy for coronary artery spasm.N Engl J Med 1980;302:1269–1273.
Kimura E, Kishida H. Treatment of variant angina with drugs: A survey of 11 cardiology in institutes in Japan.Circulation 1981;63:844–848.
Frenneaux M, Kaski J, Brown M, et al. Refractory variant angina relieved by guanethidine and clonidine.Am J Cardiol 1988;62:832–833.
Ludmer P, Selwyn A, Shook T, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries.N Engl J Med 1986;315:1046–1051.
Vanhoutte P, Shimokawa H. Endothelium-derived relaxing factor and coronary vasospasm.Circulation 1989;80:1–9.
Prinzmetal M, Kennamer R, Merliss R, et al. Angina pectoris. A variant form of angina pectoris.Am J Med 1959;27:375–388.
Maseri A, Severi S, Denes M, et al. “Variant angina”: One aspect of a continuous spectrum of vasospastic myocardial ischemia.Am J Cardiol 1978;42:1019–1035.
Specchia G, DeServi S, Falcone C, et al. Coronary arterial spasm as a cause of exercise induced ST segment elevation in patients with variant angina.Circulation 1979;59:948–954.
Waters D, Szlachcic J, Bonan R, et al. Comparative sensitivity of exercise, cold pressor and ergonovine testing in provoking attacks of variant angina in patients with active disease.Circulation 1983;67:310–315.
Kaski JC, Crea F, Meran D, et al. Local coronary supersensitivity to diverse vasoconstrictive stimuli in patients with variant angina.Circulation 1986;74:1255–1265.
Hackett D, Davies G, Chierchia S, et al. Intermittent coronary occlusion in acute myocardial infarction. Value of combined thrombolytic and vasodilator therapy.N Engl J Med 1987;317:1055–1059.
Horio Y, Yasue H, Rokutanda M, et al. Effects of intracoronary injection of acetylcholine on coronary arterial diameter.Am J Cardiol 1986;57:984–989.
Feldman RL. A review of medical therapy for coronary artery spasm.Circulation 1987;75(Suppl V):V96–102.
Kaski JC. Mechanisms of coronary artery spasm.Trends Cardiovasc Med 1991;1:289–293.
Kaski J, Maseri A, Vejar M, et al. Spontaneous coronary artery spasm in variant angina is caused by a local hyper-reactivity to a generalized constrictor stimulus.J Am Coll Cardiol 1989;14:1456–1463.
Johnson PC. The myogenic response. InHandbook of Physiology Circulation. Vascular Smooth Muscle American Physiological Society, Bethesda, MD, 1983:409–439.
Feigl EO. Coronary physiology.Physiol Rev 1983;63:1–205.
Clarke J, Davies G, Kerwin R, et al. Coronary artery infusion of neuropeptide Y in patients with angina pectoris.Lancet 1987;1:1057–1059.
Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells.Nature 1988;332:411–415.
Daut J, Maier-Rudolf W, von Beckerath N, et al. Hypoxic dilation of coronary arteries is mediated by ATP-sensitive potassium channels.Science 1990;247:1341–1344.
Gage J, Hess O, Murakami T, et al. Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris: Reversibility by nitroglycerin.Circulation 1986;73:865–876.
Crea F, Davies G, Romeo F, et al. Myocardial ischemia during ergonovine testing: Different susceptibility to coronary vasoconstriction in patients with exertional and variant angina.Circulation 1984;69:690–695.
Brown B, Bolson E, Petersen R, et al. The mechanisms of nitroglycerin action: Stenosis vasodilation as a major component of the drug response.Circulation 1981;69:1089–1097.
Kaski J, Tousoulis D, Haider A, et al. Reactivity of eccentric and concentric coronary stenoses in patients with chronic stable angina.J Am Coll Cardiol 1991;17:627–633.
Epstein S, Talbot T. Dynamic coronary tone in precipitation, exacerbation and relief of angina pectoris.Am J Cardiol 1981;48:797–803.
Tousoulis D, Kaski J, Bogaty P, et al. Reactivity of proximal and distal angiographically normal and stenotic coronary segments in chronic stable angina pectoris.Am J Cardiol 1991;67:1195–1200.
Tousoulis D, MacFadden E, Kaski J. Patterns of coronary artery stenosis vasomotion: Observed versus predicted stenosis reactivity in patients with chronic stable angina.Cor Art Dis 1993;4:529–536.
MacAlpin R. Contribution of dynamic vascular wall thickening to luminal narrowing during coronary arterial constriction.Circulation 1985;61:296–301.
Maseri A, Chierchia S, Kaski J. Mixed angina pectoris.Am J Cardiol 1985;56:30E-33E.
Kaski J, Rodriguez-Plaza L, Meran D, et al. Improved coronary supply: The prevailing mechanism of action of nitrates in chronic stable angina.Am Heart J 1985;110:238–245.
Maseri A, L'Abbate A, Baroldi G, et al. Coronary vasospasm as a possible cause of myocardial infarction. A conclusion derived from the study of “preinfarction” angina.N Engl J Med 1978;299:1271–1277.
Nakamura M, Takeshita A, Nose Y. Clinical characteristics associated with myocardial infarction, arrhythmias and sudden death in patients with vasospastic angina.Circulation 1987;75:1110–1116.
Davies M, Thomas A. Thrombosis and acute coronary artery lesions in sudden cardiac ischemic death.N Engl J Med 1984;310:1137–1140.
Davies M, Thomas A. Plaque fissuring—the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina.Br Heart J 1985;53:363–373.
Falk E. Unstable angina with fatal outcome: Dynamic coronary thrombosis leading to infarction and/or sudden death: Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion.Circulation 1985;71:699–708.
Fuster V, Chesebro J. Mechanisms of unstable angina.N Engl J Med 1986;315:1023–1025.
Fuster V, Badimon L, Cohen M, Ambrose J, Badimon J, Chesebro J. Insights into the pathogenesis of acute ischemic syndromes.Circulation 1988;77:1213–1220.
Maseri A, Chierchia S, Davies G. Pathophysiology of coronary occlusion in acute infarction.Circulation 1986;73:233–239.
Fitzgerald D, Roy L, Catella F, et al. Platelet activation in unstable coronary disease.N Engl J Med 1986;315:983–989.
Davies G, Chierchia S, Maseri A. Prevention of myocardial infarction by very early treatment with intracoronary streptokinase. Some clinical observations.N Engl J Med 1984;311:1488–1492.
Taira N, Satoh K, Yanagisawa T, et al. Pharmacological profile of a new coronary vasodilatory drug, 2-nicotinamide-ethyl-nitrate (SG75).Clin Exp Pharmacol Physiol 1979;6:301–316.
Sakai K. Nicorandil: Animal pharmacology.Am J Cardiol 1989;63:2J-10J.
Yanagisawa T, Taira N. Effect of 2-nicotinamidethyl nitrate (SG-75) on the membrane potential of left atrial muscle fibres of the dog.Naunyn Schmiedebergs Arch Pharmacol 1980;312:69–76.
Saki K, Ohba Y, Adkima M, et al. Pharmacodynamic and metabolism studies on a new coronary vasodilator, N-(2-hydroxyethyl) nicotinamidenitrate (SG-75).Jpn J Pharmacol 1980;30:881–890.
Kreye V, Lenz T, Pfrunder D, et al. Pharmacological characterization of nicorandil by Rb efflux and isometric vasorelaxation studies in vascular smooth muscle.J Cardiovasc Pharmacol 1992;20(Suppl 3):S8-S12.
Sakai K, Shirai Y, Habata H. Cardiovascular effects of a new coronary vasodilator n-2-hydroxyethyl nicotinamide nitrate SG 75: Comparison with nitroglycerin and diltiazem.J Cardiovasc Pharmacol 1981;3:139–150.
Kukovetz W, Holzmann S, Poch G. Molecular mechanism of action of nicorandil.J Cardiovasc Pharmacol 1992;20(Suppl 3):S1-S7.
Berdeaux A, Drieu la Rochelle C, Richard V, et al. Differential effects of nitrovasodilators, K+ channel openers and nicorandil on large and small coronary arteries in conscious dogs.J Cardiovasc Pharmacol 1992;20(Suppl 3):S29-S51.
Sakai K, Akima M, Shiraki Y, et al. Effects of a new antianginal agent, nicorandil, on the cardiovascular system of the miniature pig: With special reference to coronary vasospasm.J Pharmacol Exp Ther 1983;227:220–228.
Ushida Y, Yoshimoto N, Murao S. Effect of SG-75 on coronary circulation.Jpn Heart J 1978;19:112–124.
Kishida H, Murao S. Effect of a new coronary vasodilator, nicorandil, on variant angina pectoris.Clin Pharmacol Ther 1987;42:166–174.
Kishida H, Hata N, Kusama Y, et al. Angiographic response to a vasodilating drug, nicorandil, in patients with coronary artery disease.Jpn Heart J 1990;3:135–143.
Aizawa T, Ogasawara K, Nakamura F, et al. Effect of nicorandil on coronary spasm.Am J Cardiol 1989;75J–79J.
Lablanche JM, Bauters C, Leroy F, et al. Prevention of coronary spasm by nicorandil: Comparison with nifedipine.J Cardiovasc Pharmacol 1992;20(Suppl 3):S82-S85.
Suryapranata H, McLeod D. Nicorandil and cardiovascular performance in patients with coronary artery disease.J Cardiovasc Pharmacol 1992;20(Suppl 3):S54–51.
Camm A, Maltz M. A controlled single dose study of the efficacy, dose response and duration of action of nicorandil in angina pectoris.Am J Cardiol 1989;63:61J-65J.
Kinoshita M, Hashimoto K, Ohbayashi Y, et al. Comparison of antianginal activity of nicorandil, propranolol and diltiazem with reference to the antianginal mechanism.Am J Cardiol 1989;63:71J-74J.
Krumenacker M, Roland E. Clinical profile of nicorandil: An overview of its hemodynamic properties and therapeutic efficacy.J Cardiovasc Pharmacol 1992;20(Suppl 3):S93-S102.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kaski, J.C. Management of vasospastic angina—Role of nicorandil. Cardiovasc Drug Ther 9 (Suppl 2), 221–227 (1995). https://doi.org/10.1007/BF00878469
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00878469